{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009508","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.834645+00:00","generated_at":"2026-06-15T02:43:42.880436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Gain Therapeutics Q1 net loss widens to $5.1M; cash $18.8M supports ops into Q3 2024","bullets":["Net loss of $5.1M ($0.43/shr) vs $3.3M ($0.28/shr) YoY; R&D spend rose to $2.8M on pre-IND studies.","Cash and marketable securities $18.8M at March 31, 2023; ATM proceeds in April extend runway into Q3 2024.","Completed GLP toxicology for GT-02287 (GBA1 Parkinson's); Phase 1 application to Australian HREC expected mid-2023.","Secured $2.8M Innosuisse grant for GT-02287 and $1.3M EU consortium grant for AAT program.","Appointed C. Evan Ballantyne as CFO in April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009508","json":"https://secwatch.observer/filing/0001558370-23-009508.json","markdown":"https://secwatch.observer/filing/0001558370-23-009508.md","text":"https://secwatch.observer/filing/0001558370-23-009508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/0001558370-23-009508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/ganx-20230512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:43:42.880436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f254c9626a577c61549424cddbf4b109ebbbdc52","claim":"Gain Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $55,180, net income $5.1 million, EPS $0.43 per share basic and diluted.","evidence_excerpt":"CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2023 2022 Revenues: ​ ​ ​ Collaboration revenues ​ $ 55,180 ​ $ 37,538 ​ Other income ​ - ​ 7,468 ​ Total revenues ​ ​ 55,180 ​ ​ 45,006 ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ Research and development ​ ​ (2,791,205","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/0001558370-23-009508-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$55,180"},{"label":"Net income","value":"$5.1 million"},{"label":"EPS","value":"$0.43 per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}